Radiation Effective in Treating Early Prostate Cancer

Publication
Article
OncologyONCOLOGY Vol 13 No 10
Volume 13
Issue 10

Large Study Confirms Radiation therapy not only destroys prostate cancer in patients with early disease but keeps it from returning, a very large study of patients from six medical centers has found.

Large Study Confirms Radiation therapy not only destroys prostate cancer in patients with early disease but keeps it from returning, a very large study of patients from six medical centers has found.

“The study confirms and elaborates on what has been reported before by individual medical centers: radiation therapy is an effective means to treat localized (stage T1B, T1C, or T2) tumors,” said lead author William U. Shipley, MD, of Massachusetts General Hospital, Harvard Medical School, in Boston, Massachusetts.

“The multicenter nature of this study shows that previous studies using smaller numbers of patients at individual medical centers can be widely generalized,” said Anthony Zietman, md, also of Massachusetts General Hospital and Harvard Medical School.

Five-Year Follow-up Finds Patients Disease Free

All patients in the study received external-beam radiation therapy only and were followed after treatment with regular prostate-specific antigen (PSA) blood tests. The study found that 81% of patients who had a low pretreatment PSA level (less than 10 ng/mL) had no evidence of disease (ie, no consecutive rises in PSA levels) 5 years following radiation treatments. In addition, 68% of patients with a pretreatment PSA level higher than 10 ng/mL but lower than 20 ng/mL were disease free at 5-year follow-up.

Recent Videos
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Findings from a phase 1 study may inform future trial designs intended to yield longer responses with PSCA-targeted CAR T cells.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
Spatial analyses may help determine factors that influence responses to sacituzumab govitecan-containing regimens in urothelial carcinoma.
Attending educational sessions may help with understanding how to manage toxicities associated with enfortumab vedotin in rare genitourinary cancers.
Two women in genitourinary oncology discuss their experiences with figuring out when to begin a family and how to prioritize both work and children.
Over the past few decades, the prostate cancer space has evolved with increased funding for clinical trial creation and enrollment.